Upstream Bio
Update in progressUPB (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, with an emphasis on severe respiratory disorders. It is developing verekitug, which is in Phase 2 for severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease, and in Phase I for COPD. The company was founded in 2021 and is headquartered in Waltham, Massachusetts.
Company score
- Sentiment
- 0.16
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.01
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.30
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. E. Rand Sutherland M.D., M.P.H.
- Founded2021
- Employees75
- Websiteupstreambio.com
Identifiers
- ISINUS91678A1079
- FIGIBBG017Y2X923
- CUSIP91678A107
- CIK0002022626